Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease.

Power TP, Ke X, Zhao Z, Bonine NG, Cziraky MJ, Grabner M, Barron JJ, Quimbo R, Vangerow B, Toth PP.

Vasc Health Risk Manag. 2018 Feb 5;14:23-36. doi: 10.2147/VHRM.S146266. eCollection 2018.

2.

Statin-prescribing trends for primary and secondary prevention of cardiovascular disease.

Brown F, Singer A, Katz A, Konrad G.

Can Fam Physician. 2017 Nov;63(11):e495-e503. Epub 2017 Nov 14.

3.

Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study.

Schroff P, Gamboa CM, Durant RW, Oikeh A, Richman JS, Safford MM.

J Am Heart Assoc. 2017 Aug 28;6(9). pii: e005449. doi: 10.1161/JAHA.116.005449.

4.

Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use.

Huang Q, Grabner M, Sanchez RJ, Willey VJ, Cziraky MJ, Palli SR, Power TP.

Am Health Drug Benefits. 2016 Nov;9(8):434-444.

5.

Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin.

Al-Asmari AK, Ullah Z, Al Masoudi AS, Ahmad I.

J Exp Pharmacol. 2017 Apr 11;9:47-57. doi: 10.2147/JEP.S128696. eCollection 2017.

6.

Cost-effectiveness of diagnostic evaluation strategies for individuals with stable chest pain syndrome and suspected coronary artery disease.

Min JK, Gilmore A, Jones EC, Berman DS, Stuijfzand WJ, Shaw LJ, O'Day K, Danad I.

Clin Imaging. 2017 May - Jun;43:97-105. doi: 10.1016/j.clinimag.2017.01.015. Epub 2017 Feb 10.

7.

Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity.

Caughey GE, Tait K, Vitry AI, Shakib S.

Patient Prefer Adherence. 2017 Jan 21;11:131-140. doi: 10.2147/PPA.S118836. eCollection 2017.

8.

Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.

Karmali KN, Lloyd-Jones DM, Berendsen MA, Goff DC Jr, Sanghavi DM, Brown NC, Korenovska L, Huffman MD.

JAMA Cardiol. 2016 Jun 1;1(3):341-9. doi: 10.1001/jamacardio.2016.0218.

9.

Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update.

Toplak H, Ludvik B, Lechleitner M, Dieplinger H, Föger B, Paulweber B, Weber T, Watschinger B, Horn S, Wascher TC, Drexel H, Brodmann M, Pilger E, Rosenkranz A, Pohanka E, Oberbauer R, Traindl O, Roithinger FX, Metzler B, Haring HP, Kiechl S.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S216-28. doi: 10.1007/s00508-016-0993-x.

10.

Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients.

Castro MR, Simon G, Cha SS, Yawn BP, Melton LJ 3rd, Caraballo PJ.

J Gen Intern Med. 2016 May;31(5):502-8. doi: 10.1007/s11606-015-3583-0. Epub 2016 Feb 5.

11.
12.

The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA.

Elion R, Coleman M.

Curr Opin HIV AIDS. 2016 Jan;11(1):67-73. doi: 10.1097/COH.0000000000000222. Review.

13.

Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis.

Sun H, Yuan Y, Wang P, Cai R, Xia W, Huang R, Wang S.

Lipids Health Dis. 2015 Nov 2;14:140. doi: 10.1186/s12944-015-0147-6.

14.

Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial.

Kutner JS, Blatchford PJ, Taylor DH Jr, Ritchie CS, Bull JH, Fairclough DL, Hanson LC, LeBlanc TW, Samsa GP, Wolf S, Aziz NM, Currow DC, Ferrell B, Wagner-Johnston N, Zafar SY, Cleary JF, Dev S, Goode PS, Kamal AH, Kassner C, Kvale EA, McCallum JG, Ogunseitan AB, Pantilat SZ, Portenoy RK, Prince-Paul M, Sloan JA, Swetz KM, Von Gunten CF, Abernethy AP.

JAMA Intern Med. 2015 May;175(5):691-700. doi: 10.1001/jamainternmed.2015.0289. Erratum in: JAMA Intern Med. 2015 May;175(5):869.

15.

Should Statins Be Started In All Type 2 Diabetics Irrespective of LDL-Cholesterol Level?

Vasanthakumar S, Teng C.

Malays Fam Physician. 2007 Aug 31;2(2):74-5. eCollection 2007. No abstract available.

16.

Lipoprotein-associated oxidative stress: a new twist to the postprandial hypothesis.

Le NA.

Int J Mol Sci. 2014 Dec 26;16(1):401-19. doi: 10.3390/ijms16010401. Review.

17.

Does use of pooled cohort risk score overestimate the use of statin?: a retrospective cohort study in a primary care setting.

Chia YC, Lim HM, Ching SM.

BMC Fam Pract. 2014 Nov 12;15:172. doi: 10.1186/s12875-014-0172-y.

18.

Effect of simvastatin and atorvastatin on serum vitamin d and bone mineral density in hypercholesterolemic patients: a cross-sectional study.

Thabit A, Alhifany A, Alsheikh R, Namnqani S, Al-Mohammadi A, Elmorsy S, Qari M, Ardawi M.

J Osteoporos. 2014;2014:468397. doi: 10.1155/2014/468397. Epub 2014 Aug 13.

19.

Relationship between universal health outcome priorities and willingness to take medication for primary prevention of myocardial infarction.

Case SM, O'Leary J, Kim N, Tinetti ME, Fried TR.

J Am Geriatr Soc. 2014 Sep;62(9):1753-8. doi: 10.1111/jgs.12983. Epub 2014 Aug 22.

20.

Are investments in disease prevention complements? The case of statins and health behaviors.

Kaestner R, Darden M, Lakdawalla D.

J Health Econ. 2014 Jul;36:151-63. doi: 10.1016/j.jhealeco.2014.04.006. Epub 2014 Apr 16.

Supplemental Content

Support Center